Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)
https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program.
Halifax, NS:
Nova Scotia Health Authority
, 2020.
- Pamphlet Number
- 1493
- Available Online
- View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Renal Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2020
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Renal insufficiency, chronic - complications
- Anemia - drug therapy
- Hematinics - therapeutic use
- Subjects (LCSH)
- Chronic renal failure--Complications
- Hematopoietic growth factors
- Renal anemia--Chemotherapy
- Abstract
- Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
- Responsibility
- Prepared by: Renal Program
- Pamphlet Number
- 1493
